Listen
AFINITOR (everolimus), tyrosine kinase inhibitor
ONCOLOGY - Focus
Opinions on drugs -
Posted on
Sep 10 2015
Reason for request
Re-assessment of the actual benefit and of the improvement in actual benefit
Minor improvement, in combination with exemestane, in the treatment of hormone receptor-positive, HER2-negative advanced breast cancer
- AFINITOR has Marketing Authorisation, in combination with exemestane, in the treatment of hormone receptor-positive, HER2/neu-negative advanced breast cancer in postmenopausal women without symptomatic visceral disease after recurrence or progression of the disease following treatment with a non-steroidal aromatase inhibitor.
- The combination AFINITOR + AROMASINE(everolimus + exemestane) provides a minor clinical benefit in the treatment of this type of cancer.
- This combination is integrated into the treatment strategy as adjuvant treatment prior to cytotoxic chemotherapy.
Clinical Benefit
| Moderate |
- |
Clinical Added Value
| minor |
- |
Therapeutic use
|
- |
English version
Contact Us
Évaluation des médicaments
